Reading a regulatory notice rather than an article about it — what changed since

Reading a regulatory notice rather than an article about it — what changed since — setting out what I have, and where I think it stops being reliable.

Asking what a regulator's document actually says, since the summaries of it disagree.

I have the primary document open and two secondhand accounts of it that cannot both be right. The primary document is narrower than either.

My question is whether I am reading the scope of it correctly, and what the correct reading rules out as well as what it permits.

Nothing in this subcategory is legal advice, and the members who work in regulated environments are the most careful to say so.

Take the reasoning and check the arithmetic; I do not always get it right.

Research-use-only material is not approved for human use anywhere. That is a statement about the material's regulatory category rather than about its quality.

That holds under the stated conditions and I have stated them.

Read the primary regulatory document rather than a summary of it. Summaries in this area lag by a year routinely and by longer occasionally.

Same conclusion as the reply above, reached differently, which is mildly reassuring.

Agreed, and I will stop repeating the version of this I had been repeating.

Preclinical versus clinical: compounds with strong preclinical data can fail in clinical trials. Compounds with no human data are being used on theoretical grounds. The regulatory position reflects this asymmetry.

I looked this up rather than remembered it, which is the right order.

Anything written here about regulatory status should be assumed stale after twelve months, which is why the documentation pages carry review dates.

If it helps: the failure mode here is usually boring rather than dramatic.

Post #7 is the version of this I will quote in future. One addition.

Taking Reading a regulatory notice seriously for a moment rather than deflecting: the honest position is that the community has observations and no controlled comparison, and those two things support very different sentences.

Primary documents matter: regulatory positions are published in official documents. Reading the regulatory agency's website directly is more reliable than reading a forum summary of it.

That has been true for the cases I have seen and I have not seen many.

Regulatory positions change: a compound's status today might differ from its status a year from now. Citing a regulatory position is worth doing only with a date attached.

It is the sort of thing that seems obvious in retrospect and was not at the time.

If you can confirm or contradict a position for your own region, please date the answer. An undated regional claim is the least useful thing in this category.

I would put the burden of proof on the interesting explanation, not the dull one.

Taking post #11 at face value and following it one step further.

Regulatory approval is a decision about a specific product from a specific manufacturer. It does not travel to a different product containing the same molecule.

That is what the documentation says. What happens in practice is usually close.

A label change is a regulatory event with a date and a document. Citing the document is what makes a claim about labelling checkable.

The reasoning is more useful than the number, which is why I have shown it.